BI Asset Management Fondsmaeglerselskab A S Buys 36,502 Shares of Stryker Corporation $SYK

BI Asset Management Fondsmaeglerselskab A S lifted its holdings in shares of Stryker Corporation (NYSE:SYK) by 205.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 54,271 shares of the medical technology company’s stock after acquiring an additional 36,502 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Stryker were worth $20,202,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the company. Capital A Wealth Management LLC purchased a new position in shares of Stryker in the fourth quarter valued at $26,000. Goodman Advisory Group LLC bought a new stake in Stryker during the first quarter worth about $32,000. City Holding Co. boosted its holdings in Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock valued at $33,000 after acquiring an additional 74 shares during the period. Smallwood Wealth Investment Management LLC purchased a new stake in Stryker during the 1st quarter valued at about $40,000. Finally, Itau Unibanco Holding S.A. purchased a new position in Stryker during the 4th quarter valued at about $42,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $381.91 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The stock has a market cap of $146.01 billion, a price-to-earnings ratio of 50.58, a price-to-earnings-growth ratio of 2.78 and a beta of 0.91. The firm has a 50 day simple moving average of $386.77 and a 200-day simple moving average of $379.38. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.81 EPS. On average, analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on SYK shares. Evercore ISI upped their target price on Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Sanford C. Bernstein set a $450.00 price objective on Stryker in a research report on Monday, May 5th. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Friday, July 18th. Truist Financial set a $415.00 price objective on Stryker and gave the stock a “hold” rating in a research note on Monday, August 4th. Finally, Roth Mkm increased their price target on Stryker from $405.00 to $456.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $430.10.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.